Antigen receptor–intrinsic non-self: The key to understanding regulatory lymphocyte–mediated idiotypic control of adaptive immune responses

Critical Reviews in Immunology

Volumn 36, Issue 1, 2016, Pages 13-56

  Lemke, Hilmar ^a  

^a Kiel and Lungen Clinic Grosshansdorf   (Germany)

Author keywords

B cell receptor; Clonal selection theory; Idiotypic regulation; Non Self; Regulatory B cells; Regulatory T cells; Self; T cell antigen receptor; T cell vaccination

Indexed keywords

ALLOANTIBODY; ANTIIDIOTYPIC ANTIBODY; AUTOANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL INTERACTION; CELL SPECIFICITY; COMPLEMENTARITY DETERMINING REGION; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSTIMULATION; LYMPHOCYTE ACTIVATION; MOLECULAR MIMICRY; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SOMATIC HYPERMUTATION; T LYMPHOCYTE; ANIMAL; IMMUNOLOGY; LYMPHOCYTE;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; RECEPTORS, ANTIGEN, B-CELL; RECEPTORS, ANTIGEN, T-CELL;

EID: 84979939197     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevImmunol.2016016606     Document Type: Article

References (383)

1. Owen RD, Davis HP, Morgan RF. Quintuplet calves and erythrocyte mosaicism. J Hered. 1946;37(10):290-7.
2. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature. 1953;172(4379):603-6.
3. Oudin J, Michel M. Une nuovelle forme d’allotypie des globulines du serum de lapin, appare-ment liée à la function et à la spécifité des anticorps. CR Acad Sci (Paris). 1963;257:805-8. French.
4. Kunkel HG, Mannik M, Williams RC. Individual antigenic specificities of isolated antibodies. Science. 1963;140:1218-9.
5. Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris). 1974;125C(1-2):373-89.
6. Jerne NK. The generative grammar of the immune system. Embo J. 1985;4(4):847-52.
7. Burnet FM. Clonal selection theory of acquired immunity. Cambridge, UK: Cambridge University Presses; 1959.
8. Smith KA. Toward a molecular understanding of adaptive immunity: A chronology. I. Front Immunol. 2012;3:1-12.
9. Cohn M. The wisdom of hindsight. Annu Rev Immunol. 1994;12:1-62.
10. Eichmann K. The Network Collective—Rise and fall of a scientific paradigm. Basel, Switzerland: Birkhäuser; 2008.
11. Zinkernagel RM. On ‘reactivity’ versus ‘tolerance.’ Immunol Cell Biol. 2004;82(4):343-52.
12. Marshall E. Disputed results now just a footnote [news]. Science. 1996;273(5272):174-5.
13. Zinkernagel RM. Maternal antibodies, childhood infections, and autoimmune diseases. N Engl J Med. 2001;345(18):1331-5.
14. Silverstein AM. The most elegant immunological experiment of the XIX century. Nat Immunol. 2000;1(2):93-4.
15. Gustafsson E, Mattsson A, Holmdahl R, Mattsson R. Pregnancy in B-cell-deficient mice: Postpartum transfer of immunoglobulins prevents neonatal runting and death. Biol Reprod. 1994;51(6):1173-80.
16. Lemke H, Lange H, Berek C. Maternal immunization modulates the primary immune response to 2-phenyl-oxazolone in BALB/c mice. Eur J Immunol. 1994;24(12):3025-30.
17. Ismaili J, Brait M, Leo O, Urbain J. Assessment of a functional role of auto-anti-idiotypes in idiotype dominance. Eur J Immunol. 1995;25(3):830-7.
18. Martinez C, Bernabe RR, de la Hera A, Pereira P, Cazenave PA, Coutinho A. Establishment of idiotypic helper T-cell repertoires early in life. Nature. 1985;317(6039):721-3.
19. Martinez C, Toribio ML, De la Hera A, Cazenave PA, Coutinho A. Maternal transmission of idiotypic network interactions selecting available T cell repertoires. Eur J Immunol. 1986;16(11):1445-7.
20. Marcos MA, De la Hera A, Pereira P, Marquez C, Toribio M, Coutinho A, Martinez C. B cell participation in the recursive selection of T cell repertoires. Eur J Immunol. 1988;18(7):1015-20.
21. Baumgarth N, Jager GC, Herman OC, Herzenberg LA. CD4+ T cells derived from B cell-deficient mice inhibit the establishment of peripheral B cell pools. Proc Natl Acad Sci U S A. 2000;97(9):4766-71.
22. Lemke H, Lange H. Is there a maternally induced immunological imprinting phase à la Konrad Lorenz? Scand J Immunol. 1999;50(4):348-54.
23. Cohen IR. The cognitive paradigm and the immunological homunculus. Immunol Today. 1992;13(12):490-4.
24. Good RA, Varco RL, Aust JB, Zak SJ. Transplantation studies in patients with agammaglobulinemia. Ann N Y Acad Sci. 1957;64(5):882-924 [discussion, 924-8].
25. Szenberg A, Warner NL. Immunological function of thymus and bursa of Fabricius: Dissociation of Immunological responsiveness in fowls with a hormonally arrested development of lymphoid tissues. Nature. 1962;194:146-48.
26. Joao C, Ogle BM, Gay-Rabinstein C, Platt JL, Cascalho M. B cell-dependent TCR diversification. J Immunol. 2004;172(8):4709-16.
27. Abu Attieh M, Rebrovich M, Wettstein PJ, Vuk-Pavlovic Z, Limper AH, Platt JL, et al. Fitness of cell-mediated immunity independent of repertoire diversity. J Immunol. 2007;178(5):2950-60.
28. Joao C. Immunoglobulin is a highly diverse self-molecule that improves cellular diversity and function during immune reconstitution. Med Hypotheses. 2007;68(1):158-61.
29. Cascalho M, Platt JL. Novel functions of B cells. Crit Rev Immunol. 2007;27(2):141-51.
30. Coutinho A, Marquez C, Araujo PM, Pereira P, Toribio ML, Marcos MA, Martinez C. A functional idiotypic network of T helper cells and antibodies, limited to the compartment of “naturally” activated lymphocytes in normal mice. Eur J Immunol. 1987;17(6):821-5.
31. Jarrett E, Hall E. Selective suppression of IgE antibody responsiveness by maternal influence. Nature. 1979;280(5718):145-7.
32. Jarrett EE, Hall E. The development of IgE-suppressive immunocompetence in young animals: Influence of exposure to antigen in the presence or absence of maternal immunity. Immunology. 1984;53(2):365-73.
33. Seeger M, Thierse HJ, Lange H, Shaw L, Hansen H, Lemke H. Antigen-independent suppression of the IgE immune response to bee venom phospholipase A2 by maternally derived monoclonal IgG antibodies. Eur J Immunol. 1998;28(7):2124-30.
34. Lange H, Kiesch B, Linden I, Otto M, Thierse HJ, Shaw L, Maehnss K, Hansen H, Lemke H. Reversal of the adult IgE high responder phenotype in mice by maternally transferred allergen-specific monoclonal IgG antibodies during a sensitive period in early ontogeny. Eur J Immunol. 2002;32(11):3133-41.
35. Maizels N, Bothwell A. The T-cell-independent immune response to the hapten NP uses a large repertoire of heavy chain genes. Cell. 1985;43(3 Pt 2):715-20.
36. Maizels N, Lau JC, Blier PR, Bothwell A. The T-cell independent antigen, NP-ficoll, primes for a high affinity IgM anti-NP response. Mol Immunol. 1988;25(12):1277-82.
37. Lange H, Zemlin M, Tanasa RI, Trad A, Weiss T, Menning H, Lemke H. Thymus-independent type 2 antigen induces a long-term IgG-related network memory. Mol Immunol. 2008;45(10):2847-60.
38. Trad A, Tanasa RI, Lange H, Zemlin M, Schroeder HW Jr, Lemke H. Clonal progression during the T cell-dependent B cell antibody response depends on the immunoglobulin DH gene segment repertoire. Front Immunol. 2014;5(385):1-11.
39. Achiron A, Mor F, Margalit R, Cohen IR, Lider O, Miron S. Suppression of experimental autoimmune encephalomyelitis by intravenously administered polyclonal immunoglobulins. J Autoimmun. 2000;15(3):323-30.
40. Gold R, Stangel M, Dalakas MC. Drug insight: The use of intravenous immunoglobulin in neurology— Therapeutic considerations and practical issues. Nat Clin Pract Neurol. 2007;3(1):36-44.
41. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345(10):747-55.
42. Macias A, Arce S, Leon J, Mustelier G, Bombino G, Domarco A, Perez R, Lage A. Novel cross-reactive anti-idiotype antibodies with properties close to the human intravenous immunoglobulin (IVIg). Hybridoma. 1999;18(3):263-72.
43. Mouthon L, Kazatchkine MD. Autoantibodies in therapeutic preparations of human IgG (IVIg). In: Peter JB, Shoenfeld Y, editors. Autoantibodies. Amsterdam: Elsevier; 1996. p. 91-5.
44. Shoenfeld Y, Kennedy RC, Ferrone S, editors. Idiotypes in medicine: Autoimmunity, infection and cancer. Amsterdam: Elsevier Science; 1997.
45. Svetlicky N, Ortega-Hernandez OD, Mouthon L, Guillevin L, Thiesen HJ, Altman A, Kravitz MS, Blank M, Shoenfeld Y. The advantage of specific intravenous immunoglobulin (sIVIG) on regular IVIG: Experience of the last decade. J Clin Immunol. 2013;33(Suppl 1):S27-32.
46. von Gunten S, Simon HU. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: Implications for the clinical use of intravenous immunoglobulins (IVIg). Autoimmun Rev. 2008;7(6):453-6.
47. Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol. 2011;7(6):349-59.
48. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: How does IgG modulate the immune system? Nat Rev Immunol. 2013;13(3):176-89.
49. von Gunten S, Shoenfeld Y, Blank M, Branch DR, Vassilev T, Kasermann F, Bayry J, Kaveri S, Simon HU. IVIG pluripotency and the concept of Fc-sialylation: Challenges to the scientist. Nat Rev Immunol. 2014;14(5):349.
50. Schwab I, Lux A, Nimmerjahn F. Reply to IVIG pluripotency and the concept of Fc-sialylation: Challenges to the scientist. Nat Rev Immunol. 2014;14(5):349.
51. Kaveri S, Prasad N, Vassilev T, Hurez V, Pashov A, Lacroix-Desmazes S, et al. Modulation of autoimmune responses by intravenous immunoglobulin (IVIg). Mult Scler. 1997;3(2):121-8.
52. Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Siberil S, et al. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun. 2011;36(1):9-15.
53. Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol. 2008;29(12):608-15.
54. Kessel A, Ammuri H, Peri R, Pavlotzky ER, Blank M, Shoenfeld Y, Toubi E. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol. 2007;179(8):5571-5.
55. Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: A critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2008;111(2):715-22.
56. De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes.” Blood. 2008;112(8):3303-11.
57. De Groot AS, Cousens L, Mingozzi F, Martin W. Tregitope peptides: The active pharmaceutical ingredient of IVIG? Clin Dev Immunol. 2013;2013:493138.
58. Lemke H, Lange H. Generalization of single immunological experiences by idiotypically mediated clonal connections. Adv Immunol. 2002;80:203-41.
59. Cosenza H. Detection of anti-idiotype reactive cells in the response to phosphorylcholine. Eur J Immunol. 1976;6(2):114-6.
60. Fernandez C, Moller G. Antigen-induced strain-specific autoantiidiotypic antibodies modulate the immune response to dextran B 512. Proc Natl Acad Sci U S A. 1979;76(11):5944-7.
61. Goidl EA, Schrater AF, Thorbecke GH, Siskind GW. Production of auto-anti-idiotypic antibody during the normal immune response. IV. Studies of the primary and secondary responses to thymus-dependent and-independent antigens. Eur J Immunol. 1980;10(11):810-4.
62. Geha RS. Presence of circulating anti-idiotype-bearing cells after booster immunization with tetanus toxoid (TT) and inhibition of anti-TT antibody synthesis by auto-anti-idiotypic antibody. J Immunol. 1983;130(4):1634-9.
63. Arreaza EE, Gibbons JJ Jr, Siskind GW, Weksler ME. Lower antibody response to tetanus toxoid associated with higher auto-anti-idiotypic antibody in old compared with young humans. Clin Exp Immunol. 1993;92(1):169-73.
64. Urbain J, Wikler M, Franssen JD, Collignon C. Idiotypic regulation of the immune system by the induction of antibodies against anti-idiotypic antibodies. Proc Natl Acad Sci U S A. 1977;74(11):5126-30.
65. Bona CA, Heber-Katz E, Paul WE. Idiotype-anti-idiotype regulation. I. Immunization with a levan-binding myeloma protein leads to the appearance of auto-anti-(anti-idiotype) antibodies and to the activation of silent clones. J Exp Med. 1981;153(4):951-67.
66. Souza AR, Gesztesi JL, Moraes JZ, Cruz CR, Sato J, Mariano M, Lopes JD. Evidence of idiotypic modulation in the immune response to gp43, the major antigenic component of Paracoccidioides brasiliensis in both mice and humans. Clin Exp Immunol. 1998;114(1):40-8.
67. Baskin JG, Ryan TM, Vakil M, Kearney JF, Lamon EW. Thymus-dependent antiidiotype and anti-antiidiotype responses to a dinitrophenyl-specific monoclonal antibody. J Immunol. 1990;145(1):202-8.
68. Percy AJ, Harn DA. Monoclonal anti-idiotypic and anti-anti-idiotypic antibodies from mice immunized with a protective monoclonal antibody against Schistosoma mansoni. J Immunol. 1988;140(8):2760-2.
69. Hebert J, Bernier D, Boutin Y, Jobin M, Mourad W. Generation of anti-idiotypic and anti-anti-idiotypic monoclonal antibodies in the same fusion. Support of Jerne’s Network Theory. J Immunol. 1990;144(11):4256-61.
70. Polonelli L, Beninati C, Teti G, Felici F, Ciociola T, Giovati L, et al. Yeast killer toxin-like candidacidal Ab6 antibodies elicited through the manipulation of the idiotypic cascade. PLoS One. 2014;9(8):e105727.
71. Reth M, Kelsoe G, Rajewsky K. Idiotypic regulation by isologous monoclonal anti-idiotope antibodies. Nature. 1981;290(5803):257-9.
72. Rodkey LS. Autoregulation of immune responses via idiotype network interactions. Microbiol Rev. 1980;44(4):631-59.
73. Nisonoff A. Anti-Idiotypes as vaccines: Theoretical Considerations. In: Shoenfeld Y, Kennedy RC, Ferrone S, editors. Idiotypes in medicine: Autoimmunity, infection and cancer. Amsterdam: Elsevier; 1997.
74. Schuler W, Weiler E, Weiler IJ. Biological and serological comparison of syngeneic and allogeneic anti-idiotypic antibodies. Mol Immunol. 1981;18(12):1095-105.
75. Meek K, Jeske D, Alkan S, Urbain J, Capra JD. Structural characterization of syngeneic and allogeneic anti-idiotypic antibodies in the anti-arsonate system. Monogr Allergy. 1987;22:109-19.
76. Rodkey LS. Studies of idiotypic antibodies: Reactions of isologous and autologous anti-idiotypic antibodies with the same antibody preparations. J Immunol. 1976;117(3):986-9.
77. Meek K, Hasemann C, Pollok B, Alkan SS, Brait M, Slaoui M, Urbain J, Capra JD. Structural characterization of antiidiotypic antibodies. Evidence that Ab2s are derived from the germline differently than Ab1s. J Exp Med. 1989;169(2):519-33.
78. Fougereau M, Corbet S, Mazza G, Nahmias C, Schiff C. Genetic and structural basis of idiotype network. The “GAT” model. Chem Immunol. 1990;48:14-29.
79. Leclercq L, Mazie JC, Somme G, Theze J. Monoclonal anti-GAT antibodies with different fine specificities express the same public idiotype. Mol Immunol. 1982;19(8):1001-9.
80. Zaghouani H, Stanislawski M. Regulation of the response to alpha(1-3) dextran: An anti-dextran associated idiotope of BALB/c mice is also expressed on A/J anti-NIP antibodies. Mol Immunol. 1987;24(12):1237-42.
81. Jerne NK, Roland J, Cazenave PA. Recurrent idiotopes and internal images. Embo J. 1982;1(2):243-7.
82. Nisonoff A, Lamoyi E. Implications of the presence of an internal image of the antigen in anti-idiotypic antibodies: Possible application to vaccine production. Clin Immunol Immunopathol. 1981;21(3):397-406.
83. Lemke H, Tanasa RI, Trad A, Lange H. Function of maternal idiotypic and anti-idiotypic antibodies as transgenerational messengers. In: Berencsi G, editor. Maternal fetal transmission of human viruses and their influence on tumorigenesis. Dordrecht: Springer; 2012. p. 249-79.
84. Osterhaus AD, Rimmelzwaan GF, Weijer K, Uytdehaag AG. Induction of anti-viral immune response by immunization with monoclonal anti-idiotype antibodies directed to private idiotopes. Viral Immunol. 1989;2(4):255-62.
85. Fields BA, Goldbaum FA, Ysern X, Poljak RJ, Mariuzza RA. Molecular basis of antigen mimicry by an anti-idiotope. Nature. 1995;374(6524):739-42.
86. Schreiber JR, Patawaran M, Tosi M, Lennon J, Pier GB. Anti-idiotype-induced, lipopolysaccharide-specific antibody response to Pseudomonas aeruginosa. J Immunol. 1990;144(3):1023-9.
87. Magliani W, Polonelli L, Conti S, Salati A, Rocca PF, Cusumano V, Mancuso G, Teti G. Neonatal mouse immunity against group B streptococcal infection by maternal vaccination with recombinant anti-idiotypes. Nat Med. 1998;4(6):705-9.
88. Kohler H, Kieber-Emmons T, Srinivasan S, Kaveri S, Morrow WJ, Muller S, Kang CY, Raychaudhuri S. Revised immune network concepts. Clin Immunol Immunopathol. 1989;52(1):104-16.
89. Rajewsky K, Takemori T, Reth M. Analysis and regulation of V gene expression by monoclonal antibodies. In: Hämmerling GJ, Hämmerling U, Kearney JF, editors. Monoclonal antibodies and T-cell hybridomas: Perspectives and technical advances. Research Monographs in Immunology. Amsterdam: Elsevier; 1981. p. 399-409.
90. Radbruch A, Zaiss S, Kappen C, Bruggemann M, Beyreuther K, Rajewsky K. Drastic change in idiotypic but not antigen-binding specificity of an antibody by a single amino-acid substitution. Nature. 1985;315(6019):506-8.
91. Clevinger B, Schilling J, Hood L, Davie JM. Structural correlates of cross-reactive and individual idiotypic determinants on murine antibodies to alpha-(1 leads to 3) dextran. J Exp Med. 1980;151(5):1059-70.
92. Lange H, Solterbeck M, Berek C, Lemke H. Correlation between immune maturation and idiotypic network recognition. Eur J Immunol. 1996;26(9):2234-42.
93. Pollok BA, Kearney JF. Identification and characterization of an apparent germline set of auto-anti-idiotypic regulatory B lymphocytes. J Immunol. 1984;132(1):114-21.
94. Pollok BA, Kearney JF, Vakil M, Perry RP. A biological consequence of variation in the site of D-JH gene rearrangement. Nature. 1984;311(5984):376-9.
95. Eyerman MC, Wysocki L. T cell recognition of somatically-generated Ab diversity. J Immunol. 1994;152(4):1569-77.
96. Wysocki LJ, Zhang X, Smith DS, Snyder CM, Bonorino C. Somatic origin of T-cell epitopes within antibody variable regions: Significance to monoclonal therapy and genesis of systemic autoimmune disease. Immunol Rev. 1998;162:233-46.
97. Zhang X, Smith DS, Guth A, Wysocki LJ. A receptor presentation hypothesis for T cell help that recruits autoreactive B cells. J Immunol. 2001;166(3):1562-71.
98. Hestvik AL, Vartdal F, Fredriksen AB, Thompson KM, Kvale EO, Skorstad G, Bogen B, Holmoy T. T cells from multiple sclerosis patients recognize multiple epitopes on Self-IgG. Scand J Immunol. 2007;66(4):393-401.
99. Binz H, Wigzell H, Bazin H. T-cell idiotypes are linked to immunoglobulin heavy chain genes. Nature. 1976;264(5587):639-42.
100. Rajewsky K, Takemori T. Genetics, expression, and function of idiotypes. Annu Rev Immunol. 1983;1:569-607.
101. Janeway CA Jr, Broughton B, Smith LA, Marion TN, Bottomly K. Direct receptor:receptor interactions between T and B lymphocytes: Idiotypic restriction in the antibody response to a cloned helper T cell receptor. J Mol Cell Immunol. 1987;3(2):83-94.
102. Binz H, Wigzell H. Shared idiotypic determinants on B and T lymphocytes reactive against the same antigenic determinants. I. Demonstration of similar or identical idiotypes on IgG molecules and T-cell receptors with specificity for the same alloantigens. J Exp Med. 1975;142(1):197-211.
103. Rajewsky K. Cross-reacting idiotypes on antibodies and T cell receptors: How can the data be interpreted? Scand J Immunol. 1983;18:95-6.
104. Rajewsky K. Years in Cologne. Annu Rev Immunol. 2013;31:1-29.
105. Martinez C, Bragado R, de la Hera A, Toribio ML, Marcos MA, Bandeira A, et al. Functional and biochemical evidence for the recognition of T cell receptors by monoclonal antibodies to an immunoglobulin idiotype. J Mol Cell Immunol. 1986;2(6):307-13.
106. Zhou SR, Whitaker JN. Specific modulation of T cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies. J Immunol. 1993;150(4):1629-42.
107. Kim YT, Deblasio T, Thorbecke GJ, Weksler ME, Siskind GW. Production of auto-anti-idiotype antibody during the normal immune response. XIV. Evidence for the antigen-independent operation of the idiotype network. Immunology. 1989;67(2):191-6.
108. Schrater AF, Goidl EA, Thorbecke GJ, Siskind GW. Production of auto-anti-idiotypic antibody during the normal immune response to TNP-ficoll. III. Absence in nu/nu mice: Evidence for T-cell dependence of the anti-idiotypic-antibody response. J Exp Med. 1979;150(4):808-17.
109. Pierce SK, Speck NA, Gleason K, Gearhart PJ, Kohler H. Balb/c T cells have the potential to recognize the TEPC 15 prototype antibody and its somatic variants. J Exp Med. 1981;154(4):1178-87.
110. Bogen B, Malissen B, Haas W. Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol. 1986;16(11):1373-8.
111. Weiss S, Bogen B. B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc Natl Acad Sci U S A. 1989;86(1):282-6.
112. Rudensky AY, Mazel SM, Blechman JM, Yurin VL. Immunoglobulin-specific T-B cell interaction. IV. B cell presentation of idiotypic determinant(s) of monoclonal anti-surface immunoglobulin antibody to idiotope-recognizing helper T clones. Eur J Immunol. 1990;20(8):1691-6.
113. Jacobsen JT, Lunde E, Sundvold-Gjerstad V, Munthe LA, Bogen B. The cellular mechanism by which complementary Id+ and anti-Id antibodies communicate: T cells integrated into idiotypic regulation. Immunol Cell Biol. 2010;88(5):515-22.
114. Jacobsen J, Haabeth OA, Tveita AA, Schjetne KW, Munthe LA, Bogen B. Naive idiotope-specific B and T cells collaborate efficiently in the absence of dendritic cells. J Immunol. 2014;192(9):4174-83.
115. Dembic Z, Rottingen JA, Dellacasagrande J, Schenck K, Bogen B. Phagocytic dendritic cells from myelomas activate tumor-specific T cells at a single cell level. Blood. 2001;97(9):2808-14.
116. Dembic Z, Schenck K, Bogen B. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells. Proc Natl Acad Sci U S A. 2000;97:2697-702.
117. Yi Q, Holm G, Lefvert AK. Idiotype-induced T cell stimulation requires antigen presentation in association with HLA-DR molecules. Clin Exp Immunol. 1996;104(2):359-65.
118. Saha A, Chatterjee SK, Foon KA, Primus FJ, Bhattacharya-Chatterjee M. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity. Cancer Res. 2003;63(11):2844-54.
119. Lauritzsen GF, Bogen B. Idiotype-specific, major histocompatibility complex restricted T cells are of both Th1 and Th2 type. Scand J Immunol. 1991;33(6):647-56.
120. Bogen B, Weiss S. Processing and presentation of idiotypes to MHC-restricted T cells. Int Rev Immunol. 1993;10(4):337-55.
121. Lauritzsen GF, Weiss S, Bogen B. Anti-tumour activity of idiotype-specific, MHC-restricted Th1 and Th2 clones in vitro and in vivo. Scand J Immunol. 1993;37(1):77-85.
122. Chakrabarti D, Ghosh SK. Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor. I. Role of idiotypic immunoglobulin. Cell Immunol. 1992;142(1):54-66.
123. Chakrabarti D, Ghosh SK. Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor. II. Characterization of anti-idiotypic CTL lines and clones. Cell Immunol. 1992;144(2):443-54.
124. Wen YJ, Lim SH. T cells recognize the VH complementarity-determining region 3 of the idiotypic protein of B cell non-Hodgkin’s lymphoma. Eur J Immunol. 1997;27(4):1043-7.
125. Mitra-Kaushik S, Shaila MS, Karande AK, Nayak R. Idiotype and antigen-specific T cell responses in mice on immunization with antigen, antibody, and anti-idiotypic antibody. Cell Immunol. 2001;209(2):109-19.
126. Mitra-Kaushik S, Shaila MS, Karande A, Nayak R. Idiotype and anti-idiotype specific T cell responses on transplantation with hybridomas reactive to viral hemagglutinin and human tumor antigen. Immunol Lett. 2002;80(2):81-7.
127. Fagerberg J, Yi Q, Gigliotti D, Harmenberg U, Ruden U, Persson B, et al. T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. Int J Cancer. 1999;80(5):671-80.
128. Graf L, Koch N, Schirrmacher V. Expression of Ia antigens in a murine T-lymphoma variant. Mol Immunol. 1985;22(12):1371-7.
129. Barnaba V, Watts C, de Boer M, Lane P, Lanzavecchia A. Professional presentation of antigen by activated human T cells. Eur J Immunol. 1994;24(1):71-5.
130. Lal G, Shaila MS, Nayak R. Activated mouse T-cells synthesize MHC class II, process, and present morbillivirus nucleocapsid protein to primed T-cells. Cell Immunol. 2005;234(2):133-45.
131. Sun ZW, Qiu YH, Shi YJ, Tao R, Chen J, Ge Y, Hu YM, Ma HB, Shi Q, Zhang XG. Time courses of B7 family molecules expressed on activated T-cells and their biological significance. Cell Immunol. 2005;236(1-2):146-53.
132. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science. 2005;309(5732):264-8.
133. von Essen M, Bonefeld CM, Siersma V, Rasmussen AB, Lauritsen JP, Nielsen BL, Geisler C. Constitutive and ligand-induced TCR degradation. J Immunol. 2004;173(1):384-93.
134. Broeren CP, Wauben MH, Lucassen MA, Van Meurs M, Van Kooten PJ, Boog CJ, Claassen E, Van Eden W. Activated rat T cells synthesize and express functional major histocompatibility class II antigens. Immunology. 1995;84(2):193-201.
135. Elias D, Tikochinski Y, Frankel G, Cohen IR. Regulation of NOD mouse autoimmune diabetes by T cells that recognize a TCR CDR3 peptide. Int Immunol. 1999;11(6):957-66.
136. Lal G, Shaila MS, Nayak R. Activated mouse T cells downregulate, process and present their surface TCR to cognate anti-idiotypic CD4+ T cells. Immunol Cell Biol. 2006;84(2):145-53.
137. Diamond B, Kowal C, Huerta PT, Aranow C, Mackay M, DeGiorgio LA, et al. Immunity and acquired alterations in cognition and emotion: Lessons from SLE. Adv Immunol. 2006;89:289-320.
138. Lal G, Shaila MS, Nayak R. Idiotypic T cells specific for Morbillivirus nucleocapsid protein process and present their TCR to cognate anti-idiotypic CD8+ T cells. Immunol Lett. 2006;102(2):132-40.
139. Lal G, Shaila MS, Nayak R. Recombinant idiotypic TCRbeta chain immunization in mice generates antigen specific T cell response. Mol Immunol. 2006;43(10):1549-56.
140. Cohen IR. T-cell vaccination for autoimmune disease: a panorama. Vaccine. 2001;20(5-6):706-10.
141. Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature. 1981;292(5818):60-1.
142. Lider O, Reshef T, Beraud E, Ben-Nun A, Cohen IR. Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science. 1988;239(4836):181-3.
143. Jiang H, Zhang SI, Pernis B. Role of CD8+ T cells in murine experimental allergic encephalomyelitis. Science. 1992;256(5060):1213-5.
144. Howell MD, Winters ST, Olee T, Powell HC, Carlo DJ, Brostoff SW. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science. 1989;246(4930):668-70.
145. Hong J, Zang YC, Tejada-Simon MV, Li S, Rivera VM, Killian J, Zhang JZ. Reactivity and regulatory properties of human anti-idiotypic antibodies induced by T cell vaccination. J Immunol. 2000;165(12):6858-64.
146. Zang YC, Hong J, Rivera VM, Killian J, Zhang JZ. Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination. J Immunol. 2000;164(8):4011-7.
147. Kakimoto K, Katsuki M, Hirofuji T, Iwata H, Koga T. Isolation of T cell line capable of protecting mice against collagen-induced arthritis. J Immunol. 1988;140(1):78-83.
148. Early P, Huang H, Davis M, Calame K, Hood L. An immunoglobulin heavy chain variable region gene is generated from three segments of DNA: VH, D and JH. Cell. 1980;19(4):981-92.
149. Tonegawa S. Somatic generation of antibody diversity. Nature. 1983;302(5909):575-81.
150. VanDyk L, Meek K. Assembly of IgH CDR3: mechanism, regulation, and influence on antibody diversity. Int Rev Immunol. 1992;8(2-3):123-33.
151. Jung D, Alt FW. Unraveling V(D)J recombination; insights into gene regulation. Cell. 2004;116(2):299-311.
152. Jung D, Giallourakis C, Mostoslavsky R, Alt FW. Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. Annu Rev Immunol. 2006;24:541-70.
153. Schroeder HWJr., Zemlin M, Khass M, Nguyen HH, Schelonka RL. Genetic control of DH reading frame and its effect on B-cell development and antigen-specifc antibody production. Crit Rev Immunol. 2010;30(4):327-44.
154. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature. 1988;334(6181):395-402.
155. Lafaille JJ, DeCloux A, Bonneville M, Takagaki Y, Tonegawa S. Junctional sequences of T cell receptor gamma delta genes: implications for gamma delta T cell lineages and for a novel intermediate of V-(D)-J joining. Cell. 1989;59(5):859-70.
156. Gilfillan S, Dierich A, Lemeur M, Benoist C, Mathis D. Mice lacking TdT: Mature animals with an immature lymphocyte repertoire. Science. 1993;261(5125):1175-8.
157. Komori T, Okada A, Stewart V, Alt FW. Lack of N regions in antigen receptor variable region genes of TdT-deficient lymphocytes. Science. 1993;261(5125):1171-5.
158. Thai TH, Kearney JF. Isoforms of terminal deoxynucleotidyltransferase: developmental aspects and function. Adv Immunol. 2005;86:113-36.
159. Alt FW, Baltimore D. Joining of immunoglobulin heavy chain gene segments: Implications from a chromosome with evidence of three D-JH fusions. Proc Natl Acad Sci U S A. 1982;79(13):4118-22.
160. Gu H, Forster I, Rajewsky K. Sequence homologies, N sequence insertion and JH gene utilization in VHDJH joining: Implications for the joining mechanism and the ontogenetic timing of Ly1 B cell and B-CLL progenitor generation. EMBO J. 1990;9(7):2133-40.
161. Feeney AJ. Lack of N regions in fetal and neonatal mouse immunoglobulin V-D-J junctional sequences. The Journal of J Exp Med. 1990;172(5):1377-90.
162. George JF Jr, Schroeder HWJr. Developmental regulation of D beta reading frame and junctional diversity in T cell receptor-beta transcripts from human thymus. J Immunol. 1992;148(4):1230-9.
163. Gavin MA, Bevan MJ. Increased peptide promiscuity provides a rationale for the lack of N regions in the neonatal T cell repertoire. Immunity. 1995;3(6):793-800.
164. Benedict CL, Gilfillan S, Kearney JF. The long isoform of terminal deoxynucleotidyl transferase enters the nucleus and, rather than catalyzing nontemplated nucleotide addition, modulates the catalytic activity of the short isoform. J Exp Med. 2001;193(1):89-99.
165. Cabaniols JP, Fazilleau N, Casrouge A, Kourilsky P, Kanellopoulos JM. Most alpha/beta T cell receptor diversity is due to terminal deoxynucleotidyl transferase. J Exp Med. 2001;194(9):1385-90.
166. Janeway CAJr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today. 1992;13(1):11-6.
167. Thai TH, Purugganan MM, Roth DB, Kearney JF. Distinct and opposite diversifying activities of terminal transferase splice variants. Nat Immunol. 2002;3(5):457-62.
168. Meek K. Analysis of junctional diversity during B lymphocyte development. Science. 1990;250(4982):820-3.
169. Casrouge A, Beaudoing E, Dalle S, Pannetier C, Kanellopoulos J, Kourilsky P. Size estimate of the alpha beta TCR repertoire of naive mouse splenocytes. J Immunol. 2000;164(11):5782-7.
170. Garcia KC, Degano M, Stanfield RL, Brunmark A, Jackson MR, Peterson PA, Teyton L, Wilson IA. An alphabeta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science. 1996;274(5285):209-19.
171. Reinherz EL, Tan K, Tang L, Kern P, Liu J, Xiong Y, et al. The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science. 1999;286(5446):1913-21.
172. Hennecke J, Wiley DC. T cell receptor-MHC interactions up close. Cell. 2001;104(1):1-4.
173. Garcia KC, Adams EJ. How the T cell receptor sees antigen—A structural view. Cell. 2005;122(3):333-6.
174. Medzhitov R, Janeway CAJr. Innate immunity: Impact on the adaptive immune response. Curr Opin Immunol. 1997;9(1):4-9.
175. Janeway CAJr., Goodnow CC, Medzhitov R. Danger—Pathogen on the premises! Immunological tolerance. Curr Biol. 1996;6(5):519-22.
176. Lemke H, Coutinho A, Lange H. Lamarckian inheritance by somatically acquired maternal IgG phenotypes. Trends Immunol. 2004;25(4):180-6.
177. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, Hiepe F. Competence and competition: The challenge of becoming a long-lived plasma cell. Nat Rev Immunol. 2006;6(10):741-50.
178. Berek C, Milstein C. Mutation drift and repertoire shift in the maturation of the immune response. Immunol Rev. 1987;96:23-41.
179. Feeney AJ, Clarke SH, Mosier DE. Specific H chain junctional diversity may be required for non-T15 antibodies to bind phosphorylcholine. J Immunol. 1988;141(4):1267-72.
180. Kalinke U, Bucher EM, Ernst B, Oxenius A, Roost HP, Geley S, et al. The role of somatic mutation in the generation of the protective humoral immune response against vesicular stomatitis virus. Immunity. 1996;5(6):639-52.
181. Lange H, Hecht O, Zemlin M, Trad A, Tanasa RI, Schroeder HWJr., Lemke H. Immunoglobulin class switching appears to be regulated by B-cell antigen receptor-specific T-cell action. Eur J Immunol. 2012;42(4):1016-29.
182. Lavinder JJ, Wine Y, Giesecke C, Ippolito GC, Horton AP, Lungu OI, et al. Identification and characterization of the constituent human serum antibodies elicited by vaccination. Proc Natl Acad Sci U S A. 2014;111(6):2259-64.
183. Pelletier N, McHeyzer-Williams LJ, Wong KA, Urich E, Fazilleau N, McHeyzer-Williams MG. Plasma cells negatively regulate the follicular helper T cell program. Nat Immunol. 2010;11(12):1110-8.
184. Jang E, Cho WS, Oh YK, Cho ML, Kim JM, Paik DJ, Youn J. Splenic long-lived plasma cells promote the development of follicular helper T cells during autoimmune responses. J Immunol. 2016; 196(3): 1026-35.
185. Lange H, Lemke H. Induction of a non-oscillating, long-lasting humoral immune response to an internal network antigen. Int Immunol. 1996;8(5):683-8.
186. Hampe CS. Protective role of anti-idiotypic antibodies in autoimmunity—Lessons for type 1 diabetes. Autoimmunity. 2012;45(4):320-31.
187. Pan ZJ, Anderson CJ, Stafford HA. Anti-idiotypic antibodies prevent the serologic detection of antiribosomal P autoantibodies in healthy adults. J Clin Invest. 1998;102(1):215-22.
188. Wang X, Zhang A, Liu Y, Chen S, Feng Z, Shang W, Maziarz M, Radtke J, Hampe CS. Anti-idiotypic antibody specific to GAD65 autoantibody prevents type 1 diabetes in the NOD mouse. PLoS One. 2012;7(2):e32515.
189. Weisbart RH, Noritake DT, Wong AL, Chan G, Kacena A, Colburn KK. A conserved anti-DNA antibody idiotype associated with nephritis in murine and human systemic lupus erythematosus. J Immunol. 1990;144(7):2653-8.
190. Spertini F, Leimgruber A, Morel B, Khazaeli MB, Yamamoto K, Dayer JM, et al. Idiotypic vaccination with a murine anti-dsDNA antibody: Phase I study in patients with nonactive systemic lupus erythematosus with nephritis. J Rheumatol. 1999;26(12):2602-8.
191. Mehta YS, Ghosh K, Badakere SS, Pathare AV, Mohanty D. Role of antiidiotypic antibodies on the clinical course of idiopathic thrombocytopenic purpura. J Lab Clin Med. 2003;142(2):113-20.
192. Pan ZJ, Anderson CJ, Stafford HA. A murine monoclonal anti-idiotype to anti-ribosomal P antibodies: Production, characterization, and use in systemic lupus erythematosus. Clin Immunol. 2001;100(3):289-97.
193. Oak S, Gilliam LK, Landin-Olsson M, Torn C, Kockum I, Pennington CR, Rowley MJ, Christie MR, Banga JP, Hampe CS. The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes. Proc Natl Acad Sci U S A. 2008;105(14):5471-6.
194. Cui Z, Zhao MH, Segelmark M, Hellmark T. Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals. Kidney Int. 2010;78(6):590-7.
195. O’Shea JJ, Kanno Y, Chan AC. In search of magic bullets: The golden age of immunotherapeutics. Cell. 2014;157(1):227-40.
196. Gomez-Mantilla JD, Troconiz IF, Parra-Guillen Z, Garrido MJ. Review on modeling anti-antibody responses to monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2014;41(5):523-36.
197. Mirick GR, Bradt BM, Denardo SJ, Denardo GL. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging. 2004;48(4):251-7.
198. Baert F, Noman M, Vermeire S, Van Assche G, D’Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601-8.
199. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68(11):1739-45.
200. Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, Romagnani S, Maggi E. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy. 2010;65(5):657-61.
201. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: A real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165-78.
202. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010;10(5):301-16.
203. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010;10(5):345-52.
204. Getts DR, Getts MT, McCarthy DP, Chastain EM, Miller SD. Have we overestimated the benefit of human(ized) antibodies? mAbs. 2010;2(6):682-94.
205. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460-8.
206. Nechansky A. HAHA—Nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology. J Pharm Biomed Anal. 2010;51(1):252-4.
207. Hall B, Kiely C, Tobin AM, McNamara D. HAHA antibodies—Not such a funny story. J Crohns Colitis. 2014;8(5):439-40.
208. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions. mAbs. 2010;2(3):256-65.
209. Gonzales NR, De Pascalis R, Schlom J, Kashmiri SV. Minimizing the immunogenicity of antibodies for clinical application. Tumour Biol. 2005;26(1):31-43.
210. Hanf KJ, Arndt JW, Chen LL, Jarpe M, Boriack-Sjodin PA, Li Y, et al. Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework. Methods. 2014;65(1):68-76.
211. Fagerberg J, Frodin JE, Wigzell H, Mellstedt H. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy? Cancer Immunol Immunother. 1993;37(4):264-70.
212. Fagerberg J, Frodin JE, Ragnhammar P, Steinitz M, Wigzell H, Mellstedt H. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy? Cancer Immunol Immunother. 1994;38(3):149-59.
213. Fagerberg J, Hjelm AL, Ragnhammar P, Frodin JE, Wigzell H, Mellstedt H. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res. 1995;55(9):1824-7.
214. Fagerberg J, Steinitz M, Wigzell H, Askelof P, Mellstedt H. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci U S A. 1995;92(11):4773-7.
215. Fagerberg J, Ragnhammar P, Liljefors M, Hjelm AL, Mellstedt H, Frodin JE. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol Immunother. 1996;42(2):81-7.
216. Urbain-Vansanten G. Concomitant synthesis, in separate cells, of non-reactive immunoglobulins and specific antibodies after immunization with tobacco mosaic virus. Immunology. 1970;19(5):783-97.
217. De Vos-Cloetens C, Minsart-Baleriaux V, Urbain-Vansanten G. Possible relationships between antibodies and non-specific immunoglobulins simultaneously induced after antigenic stimulation. Immunology. 1971;20(6):955-62.
218. Rosenberg YJ, Chiller JM. Ability of antigen-specific helper cells to effect a class-restricted increase in total Ig-secreting cells in spleens after immunization with the antigen. J Exp Med. 1979;150(3):517-30.
219. Rosenberg YJ, Asofsky R. T cell regulation of isotype expression. The requirement for a second Ig-specific helper T cell population for the induction of IgG responses. Eur J Immunol. 1981;11(9):705-10.
220. Cazenave PA, Ternynck T, Avrameas S. Similar idiotypes in antibody-forming cells and in cells synthesizing immunoglobulins without detectable antibody function. Proc Natl Acad Sci U S A. 1974;71(11):4500-2.
221. Bottomly K, Mathieson BJ, Mosier DE. Anti-idiotype induced regulation of helper cell function for the response to phosphorylcholine in adult BALB/c mice. J Exp Med. 1978;148(5):1216-27.
222. Woodland R, Cantor H. Idiotype-specific T helper cells are required to induce idiotype-positive B memory cells to secrete antibody. Eur J Immunol. 1978;8(8):600-6.
223. L’Age-Stehr J. Priming of T helper cells by antigen-activated B cells. B cell-primed Lyt-1+ helper cells are restricted to cooperate with B cells expressing the IgvH phenotype of the priming B cells. J Exp Med. 1981;153(5):1236-45.
224. Rademaekers A, Specht C, Kolsch E. T-cell enforced invariance of the antibody repertoire in the immune response against a bacterial carbohydrate antigen. Scand J Immunol. 2001;53(3):240-4.
225. Pride MW, Shi H, Anchin JM, Linthicum DS, LoVerde PT, Thakur A, Thanavala Y. Molecular mimicry of hepatitis B surface antigen by an anti-idiotype-derived synthetic peptide. Proc Natl Acad Sci U S A. 1992;89(24):11900-4.
226. Yang YF, Thanavala Y. A comparison of the antibody and T cell response elicited by internal image and noninternal image anti-idiotypes. Clin Immunol Immunopathol. 1995;75(2):154-8.
227. Bruck C, Co MS, Slaoui M, Gaulton GN, Smith T, Fields BN, Mullins JI, Greene M. Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen. Proc Natl Acad Sci U S A. 1986;83(17):6578-82.
228. Gangadhar V, Jeyakani JJ, Shaila MS, Nayak R, Chandra N. Perpetuation of immunological memory through common MHC-I binding modes of peptidomimic and antigenic peptides. Biochem Biophys Res Commun. 2007;364(2):308-12.
229. Lemke H, Tanasa RI, Trad A, Lange H. Benefits and burden of the maternally-mediated immunological imprinting. Autoimmun Rev. 2009;8(5):394-9.
230. Okamoto Y, Tsutsumi H, Kumar NS, Ogra PL. Effect of breast feeding on the development of anti-idiotype antibody response to F glycoprotein of respiratory syncytial virus in infant mice after post-partum maternal immunization. J Immunol. 1989;142(7):2507-12.
231. Stein KE, Söderström T. Neonatal administration of idiotype or antiidiotype primes for protection against Escherichia coli K13 infection in mice. J Exp Med. 1984;160(4):1001-11.
232. Tanasa RI, Trad A, Lange H, Grotzinger J, Lemke H. Allergen IgE-isotype-specific suppression by maternally derived monoclonal anti-IgG-idiotype. Allergy. 2010;65(1):16-23.
233. Wetterwald A, Toffler O, de Weck AL, Blaser K. Suppression of established IgE antibody responses with isologous anti-idiotypic antibodies in guinea pigs. Mol Immunol. 1986;23(3):347-56.
234. Rodkey LS, Adler FL. Regulation of natural antiallotype antibody responses by idiotype network-induced auto-antiidiotypic antibodies. J Exp Med. 1983;157(6):1920-31.
235. Coutinho A, Caramalho I, Seixas E, Demengeot J. Thymic commitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoing positive or negative selection. Curr Top Microbiol Immunol. 2005;293:43-71.
236. Smith TR, Kumar V. Revival of CD8+ Treg-mediated suppression. Trends Immunol. 2008;29(7):337-42.
237. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: A jack of all trades, master of regulation. Nat Immunol. 2008;9(3):239-44.
238. Germain RN. Special regulatory T-cell review: A rose by any other name: from suppressor T cells to Tregs, approbation to unbridled enthusiasm. Immunology. 2008;123(1):20-7.
239. Workman CJ, Szymczak-Workman AL, Collison LW, Pillai MR, Vignali DA. The development and function of regulatory T cells. Cell Mol Life Sci. 2009;66(16):2603-22.
240. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: Mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531-64.
241. Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol. 2012;30:221-41.
242. Sakaguchi S, Vignali DA, Rudensky AY, Niec RE, Waldmann H. The plasticity and stability of regulatory T cells. Nat Rev Immunol. 2013;13(6):461-7.
243. Shen P, Fillatreau S. Antibody-independent functions of B cells: a focus on cytokines. Nat Rev Immunol. 2015;15(7):441-51.
244. Kyewski B, Derbinski J. Self-representation in the thymus: An extended view. Nat Rev Immunol. 2004;4(9):688-98.
245. Klein L, Kyewski B, Allen PM, Hogquist KA. Positive and negative selection of the T cell repertoire: What thymocytes see (and don’t see). Nat Rev Immunol. 2014;14(6):377-91.
246. Coutinho A, Carneiro-Sampaio M. Primary immunodeficiencies unravel critical aspects of the pathophysiology of autoimmunity and of the genetics of autoimmune disease. J Clin Immunol. 2008;28(Suppl 1):S4-10.
247. Yan J, Mamula MJ. Autoreactive T cells revealed in the normal repertoire: Escape from negative selection and peripheral tolerance. J Immunol. 2002;168(7):3188-94.
248. Detanico T, Heiser RA, Aviszus K, Bonorino C, Wysocki LJ. Self-tolerance checkpoints in CD4 T cells specific for a peptide derived from the B cell antigen receptor. J Immunol. 2011;187(1):82-91.
249. Guo W, Smith D, Aviszus K, Detanico T, Heiser RA, Wysocki LJ. Somatic hypermutation as a generator of antinuclear antibodies in a murine model of systemic autoimmunity. J Exp Med. 2010;207(10):2225-37.
250. Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, Wardemann H. Autoreactivity in human IgG+ memory B cells. Immunity. 2007;26(2):205-13.
251. Lohse AW, Mor F, Karin N, Cohen IR. Control of experimental autoimmune encephalomyelitis by T cells responding to activated T cells. Science. 1989;244(4906):820-2.
252. Quintana FJ, Cohen IR. Anti-ergotypic immunoregulation. Scand J Immunol. 2006;64(3):205-10.
253. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151-64.
254. del Rio R, Sun Y, Alard P, Tung KS, Teuscher C. H2 control of natural T regulatory cell frequency in the lymph node correlates with susceptibility to day 3 thymectomy-induced autoimmune disease. J Immunol. 2011;186(1):382-9.
255. Tokunaga Y, Hiramine C, Itoh M, Mukasa A, Hojo K. Genetic susceptibility to the induction of murine experimental autoimmune orchitis (EAO) without adjuvant. I. Comparison of pathology, delayed type hypersensitivity, and antibody. Clin Immunol Immunopathol. 1993;66(3):239-47.
256. Nair S, Caspi RR, Nelson LM. Susceptibility to murine experimental autoimmune oophoritis is associated with genes outside the major histocompatibility complex (MHC). Am J Reprod Immunol. 1996;36(2):107-10.
257. Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol. 2013;14(4):307-8.
258. Taguchi O, Nishizuka Y, Sakakura T, Kojima A. Autoimmune oophoritis in thymectomized mice: Detection of circulating antibodies against oocytes. Clin Exp Immunol. 1980;40(3):540-53.
259. Samy ET, Wheeler KM, Roper RJ, Teuscher C, Tung KS. Cutting edge: Autoimmune disease in day 3 thymectomized mice is actively controlled by endogenous disease-specific regulatory T cells. J Immunol. 2008;180(7):4366-70.
260. Setiady YY, Agersborg S, Samy ET, Lewis JE, Tung KS. Neonatal autoimmune disease: Influence of CD4+ CD25+ regulatory T cells. Int Rev Immunol. 2005;24(3-4):227-45.
261. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4(4):330-6.
262. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057-61.
263. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001;27(1):68-73.
264. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27(1):20-1.
265. Zhang ZX, Young K, Zhang L. CD3+CD4-CD8-alphabeta-TCR+ T cell as immune regulatory cell. J Mol Med. 2001;79(8):419-27.
266. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531-62.
267. Dinesh RK, Skaggs BJ, La Cava A, Hahn BH, Singh RP. CD8+ Tregs in lupus, autoimmunity, and beyond. Autoimmun Rev. 2010;9(8):560-8.
268. Malek TR, Yu A, Vincek V, Scibelli P, Kong L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity. 2002;17(2):167-78.
269. Rifa’i M, Kawamoto Y, Nakashima I, Suzuki H. Essential roles of CD8+CD122+ regulatory T cells in the maintenance of T cell homeostasis. J Exp Med. 2004;200(9):1123-34.
270. Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol. 2007;37(1):129-38.
271. Curotto de Lafaille MA, Lino AC, Kutchukhidze N, Lafaille JJ. CD25-T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion. J Immunol. 2004;173(12):7259-68.
272. Fischer K, Voelkl S, Heymann J, Przybylski GK, Mondal K, Laumer M, Kunz-Schughart L, et al. Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(-)CD8-double-negative regulatory T cells. Blood. 2005;105(7):2828-35.
273. Voelkl S, Gary R, Mackensen A. Characterization of the immunoregulatory function of human TCR-alphabeta+ CD4-CD8-double-negative T cells. Eur J Immunol. 2011;41(3):739-48.
274. Allan SE, Passerini L, Bacchetta R, Crellin N, Dai M, Orban PC, et al. The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J Clin Invest. 2005;115(11):3276-84.
275. Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of regulatory T cells. Immunity. 2013;38(3):414-23.
276. Kang N, Tang L, Li X, Wu D, Li W, Chen X, et al. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human. Immunol Lett. 2009;125(2):105-13.
277. Pillai V, Ortega SB, Wang CK, Karandikar NJ. Transient regulatory T-cells: A state attained by all activated human T-cells. Clin Immunol. 2007;123(1):18-29.
278. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol. 2007;19(4):345-54.
279. Ziegler SF. FOXP3: Not just for regulatory T cells anymore. Eur J Immunol. 2007;37(1):21-3.
280. Duhen T, Duhen R, Lanzavecchia A, Sallusto F, Campbell DJ. Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood. 2012;119(19):4430-40.
281. Sakaguchi S. Regulatory T cells: Key controllers of immunologic self-tolerance. Cell. 2000;101(5):455-8.
282. DiLillo DJ, Yanaba K, Tedder TF. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: Therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol. 2010;184(7):4006-16.
283. Karpus WJ, Swanborg RH. Protection against experimental autoimmune encephalomyelitis requires both CD4+ T suppressor cells and myelin basic protein-primed B cells. J Neuroimmunol. 1991;33(2):173-7.
284. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002;3(10):944-50.
285. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity. J Immunol. 1999;163(10):5211-8.
286. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev. 2008;224:201-14.
287. Kalampokis I, Yoshizaki A, Tedder TF. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther. 2013;15(Suppl 1):S1.
288. Yanaba K, Bouaziz JD, Matsushita T, Tsubata T, Tedder TF. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol. 2009;182(12):7459-72.
289. DiLillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci. 2010;1183:38-57.
290. Lykken JM, Candando KM, Tedder TF. Regulatory B10 cell development and function. Int Immunol. 2015;27(10):471-7.
291. Mauri C, Menon M. The expanding family of regulatory B cells. Int Immunol. 2015;27:479-86.
292. Zhang Y, Gallastegui N, Rosenblatt JD. Regulatory B cells in anti-tumor immunity. Int Immunol. 2015;27:521-30.
293. Ray A, Basu S, Williams CB, Salzman NH, Dittel BN. A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand. J Immunol. 2012;188(7):3188-98.
294. Ronchetti S, Ricci E, Petrillo MG, Cari L, Migliorati G, Nocentini G, et al. Glucocorticoid-induced tumour necrosis factor receptor-related protein: A key marker of functional regulatory T cells. J Immunol Res. 2015;2015:171520.
295. Petrillo MG, Ronchetti S, Ricci E, Alunno A, Gerli R, Nocentini G, et al. GITR+ regulatory T cells in the treatment of autoimmune diseases. Autoimmun Rev. 2015;14(2):117-26.
296. Samoilova EB, Horton JL, Chen Y. Acceleration of experimental autoimmune encephalomyelitis in interleukin-10-deficient mice: Roles of interleukin-10 in disease progression and recovery. Cell Immunol. 1998;188(2):118-24.
297. Bettelli E, Das MP, Howard ED, Weiner HL, Sobel RA, Kuchroo VK. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10-and IL-4-deficient and transgenic mice. J Immunol. 1998;161(7):3299-306.
298. Heine G, Niesner U, Chang HD, Steinmeyer A, Zugel U, Zuberbier T, et al. 1,25-dihydroxyvitamin D(3) promotes IL-10 production in human B cells. Eur J Immunol. 2008;38(8):2210-8.
299. Shen P, Fillatreau S. Suppressive functions of B cells in infectious diseases. Int Immunol. 2015;27(10):513-9.
300. Yoshizaki A, Miyagaki T, DiLillo DJ, Matsushita T, Horikawa M, Kountikov EI, et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature. 2012;491(7423):264-8.
301. Xing C, Ma N, Xiao H, Wang X, Zheng M, Han G, et al. Critical role for thymic CD19+CD5+CD1dhiIL-10+ regulatory B cells in immune homeostasis. J Leukoc Biol. 2015;97(3):547-56.
302. Miyama-Inaba M, Kuma S, Inaba K, Ogata H, Iwai H, Yasumizu R, Muramatsu S. Unusual phenotype of B cells in the thymus of normal mice. J Exp Med. 1988;168(2):811-6.
303. Mori S, Inaba M, Sugihara A, Taketani S, Doi H, Fukuba Y, et al. Presence of B cell progenitors in the thymus. J Immunol. 1997;158(9):4193-9.
304. Inaba M, Inaba K, Adachi Y, Nango K, Ogata H, Muramatsu S, et al. Functional analyses of thymic CD5+ B cells. Responsiveness to major histocompatibility complex class II-restricted T blasts but not to lipopolysaccharide or anti-IgM plus interleukin 4. J Exp Med. 1990;171(1):321-6.
305. Akashi K, Richie LI, Miyamoto T, Carr WH, Weissman IL. B lymphopoiesis in the thymus. J Immunol. 2000;164(10):5221-6.
306. Perera J, Huang H. The development and function of thymic B cells. Cell Mol Life Sci. 2015;72(14):2657-63.
307. Kleindienst P, Chretien I, Winkler T, Brocker T. Functional comparison of thymic B cells and dendritic cells in vivo. Blood. 2000;95(8):2610-6.
308. Frommer F, Waisman A. B cells participate in thymic negative selection of murine auto-reactive CD4+ T cells. PLoS One. 2010;5(10):e15372.
309. Lu FT, Yang W, Wang YH, Ma HD, Tang W, Yang JB, et al. Thymic B cells promote thymus-derived regulatory T cell development and proliferation. J Autoimmun. 2015;61:62-72.
310. Sun JB, Flach CF, Czerkinsky C, Holmgren J. B lymphocytes promote expansion of regulatory T cells in oral tolerance: Powerful induction by antigen coupled to cholera toxin B subunit. J Immunol. 2008;181(12):8278-87.
311. Tadmor T, Zhang Y, Cho HM, Podack ER, Rosenblatt JD. The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model. Cancer Immunol Immunother. 2011;60(5):609-19.
312. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008;118(10):3420-30.
313. Matsushita T, Horikawa M, Iwata Y, Tedder TF. Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J Immunol. 2010;185(4):2240-52.
314. Alexander CM, Tygrett LT, Boyden AW, Wolniak KL, Legge KL, Waldschmidt TJ. T regulatory cells participate in the control of germinal centre reactions. Immunology. 2011;133(4):452-68.
315. Linterman MA, Pierson W, Lee SK, Kallies A, Kawamoto S, Rayner TF, et al.. Foxp3+ follicular regulatory T cells control the germinal center response. Nat Med. 2011;17(8):975-82.
316. Chung Y, Tanaka S, Chu F, Nurieva RI, Martinez GJ, Rawal S, et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med. 2011;17(8):983-8.
317. Wing JB, Sakaguchi S. Foxp3(+) T(reg) cells in humoral immunity. Int Immunol. 2014;26(2):61-9.
318. Hogquist KA, Baldwin TA, Jameson SC. Central tolerance: Learning self-control in the thymus. Nat Rev Immunol. 2005;5(10):772-82.
319. Kronenberg M, Rudensky A. Regulation of immunity by self-reactive T cells. Nature. 2005;435(7042):598-604.
320. Seddon B, Mason D. Peripheral autoantigen induces regulatory T cells that prevent autoimmunity. J Exp Med. 1999;189(5):877-82.
321. Jordan MS, Boesteanu A, Reed AJ, Petrone AL, Holenbeck AE, Lerman MA, et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol. 2001;2(4):301-6.
322. Cozzo C, Larkin J3rd, Caton AJ. Cutting edge: Self-peptides drive the peripheral expansion of CD4+CD25+ regulatory T cells. J Immunol. 2003;171(11):5678-82.
323. Andersson J, Stefanova I, Stephens GL, Shevach EM. CD4+CD25+ regulatory T cells are activated in vivo by recognition of self. Int Immunol. 2007;19(4):557-66.
324. Hsieh CS, Liang Y, Tyznik AJ, Self SG, Liggitt D, Rudensky AY. Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity. 2004;21(2):267-77.
325. Fontenot JD, Dooley JL, Farr AG, Rudensky AY. Developmental regulation of Foxp3 expression during ontogeny. J Exp Med. 2005;202(7):901-6.
326. Hsieh CS, Zheng Y, Liang Y, Fontenot JD, Rudensky AY. An intersection between the self-reactive regulatory and nonregulatory T cell receptor repertoires. Nat Immunol. 2006;7(4):401-10.
327. Romagnoli P, Hudrisier D, van Meerwijk JP. Preferential recognition of self antigens despite normal thymic deletion of CD4(+)CD25(+) regulatory T cells. J Immunol. 2002;168(4):1644-8.
328. Pacholczyk R, Ignatowicz H, Kraj P, Ignatowicz L. Origin and T cell receptor diversity of Foxp3+CD4+CD25+ T cells. Immunity. 2006;25(2):249-59.
329. Relland LM, Williams JB, Relland GN, Haribhai D, Ziegelbauer J, Yassai M, et al. The TCR repertoires of regulatory and conventional T cells specific for the same foreign antigen are distinct. J Immunol. 2012;189(7):3566-74.
330. Pacholczyk R, Kern J, Singh N, Iwashima M, Kraj P, Ignatowicz L. Nonself-antigens are the cognate specificities of Foxp3+ regulatory T cells. Immunity. 2007;27(3):493-504.
331. Stephens GL, Shevach EM. Foxp3+ regulatory T cells: Selfishness under scrutiny. Immunity. 2007;27(3):417-9.
332. Cebula A, Seweryn M, Rempala GA, Pabla SS, McIndoe RA, Denning TL, et al. Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota. Nature. 2013;497(7448):258-62.
333. Hori S, Haury M, Coutinho A, Demengeot J. Specificity requirements for selection and effector functions of CD25+4+ regulatory T cells in anti-myelin basic protein T cell receptor transgenic mice. Proc Natl Acad Sci U S A. 2002;99(12):8213-8.
334. Reddy J, Illes Z, Zhang X, Encinas J, Pyrdol J, Nicholson L, et al. Myelin proteolipid protein-specific CD4+CD25+ regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2004;101(43):15434-9.
335. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med. 2004;199(11):1467-77.
336. Samy ET, Parker LA, Sharp CP, Tung KS. Continuous control of autoimmune disease by antigen-dependent polyclonal CD4+CD25+ regulatory T cells in the regional lymph node. J Exp Med. 2005;202(6):771-81.
337. Annacker O, Burlen-Defranoux O, Pimenta-Araujo R, Cumano A, Bandeira A. Regulatory CD4 T cells control the size of the peripheral activated/ memory CD4 T cell compartment. J Immunol. 2000;164(7):3573-80.
338. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 2002;420(6915):502-7.
339. Suvas S, Kumaraguru U, Pack CD, Lee S, Rouse BT. CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses. J Exp Med. 2003;198(6):889-901.
340. Ochando JC, Yopp AC, Yang Y, Garin A, Li Y, Boros P, et al. Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. J Immunol. 2005;174(11):6993-7005.
341. Föhse L, Suffner J, Suhre K, Wahl B, Lindner C, Lee CW, et al. High TCR diversity ensures optimal function and homeostasis of Foxp3+ regulatory T cells. Eur J Immunol. 2011;41(11):3101-13.
342. Lerman MA, Larkin J3rd, Cozzo C, Jordan MS, Caton AJ. CD4+ CD25+ regulatory T cell repertoire formation in response to varying expression of a neo-self-antigen. J Immunol. 2004;173(1):236-44.
343. Larkin J 3rd, Picca CC, Caton AJ. Activation of CD4+ CD25+ regulatory T cell suppressor function by analogs of the selecting peptide. Eur J Immunol. 2007;37(1):139-46.
344. Lafaille JJ, Nagashima K, Katsuki M, Tonegawa S. High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell. 1994;78(3):399-408.
345. Van de Keere F, Tonegawa S. CD4(+) T cells prevent spontaneous experimental autoimmune encephalomyelitis in anti-myelin basic protein T cell receptor transgenic mice. J Exp Med. 1998;188(10):1875-82.
346. Olivares-Villagomez D, Wang Y, Lafaille JJ. Regulatory CD4(+) T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. J Exp Med. 1998;188(10):1883-94.
347. Oh S, Aitken M, Simons DM, Basehoar A, Garcia V, Kropf E, et al. Requirement for diverse TCR specificities determines regulatory T cell activity in a mouse model of autoimmune arthritis. J Immunol. 2012;188(9):4171-80.
348. Wing JB, Sakaguchi S. TCR diversity and Treg cells, sometimes more is more. Eur J Immunol. 2011;41(11):3097-100.
349. Zhang J, Stinissen P, Medaer R, Raus J. T cell vaccination: Clinical application in autoimmune diseases. J Mol Med. 1996;74(11):653-62.
350. Jiang H, Chess L. The specific regulation of immune responses by CD8+ T cells restricted by the MHC class Ib molecule, Qa-1. Annu Rev Immunol. 2000;18:185-216.
351. Cohen IR, Quintana FJ, Mimran A. Tregs in T cell vaccination: Exploring the regulation of regulation. J Clin Invest. 2004;114(9):1227-32.
352. Vandenbark AA, Offner H. Critical evaluation of regulatory T cells in autoimmunity: Are the most potent regulatory specificities being ignored? Immunology. 2008;125(1):1-13.
353. Volovitz I, Marmor Y, Mor F, Flugel A, Odoardi F, Eisenbach L, et al. T cell vaccination induces the elimination of EAE effector T cells: Analysis using GFP-transduced, encephalitogenic T cells. J Autoimmun. 2010;35(2):135-44.
354. Tikochinski Y, Elias D, Steeg C, Marcus H, Kantorowitz M, Reshef T, et al. A shared TCR CDR3 sequence in NOD mouse autoimmune diabetes. Int Immunol. 1999;11(6):951-6.
355. Zang YC, Hong J, Tejada-Simon MV, Li S, Rivera VM, Killian JM, et al. Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis. Eur J Immunol. 2000;30(3):908-13.
356. Sun D, Qin Y, Chluba J, Epplen JT, Wekerle H. Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T-T cell interactions. Nature. 1988;332(6167):843-5.
357. Sun D, Ben-Nun A, Wekerle H. Regulatory circuits in autoimmunity: Recruitment of counter-regulatory CD8+ T cells by encephalitogenic CD4+ T line cells. Eur J Immunol. 1988;18(12):1993-9.
358. Varthaman A, Clement M, Khallou-Laschet J, Fornasa G, Gaston AT, Dussiot M, et al. Physiological induction of regulatory Qa-1-restricted CD8+ T cells triggered by endogenous CD4+ T cell responses. PLoS One. 2011;6(6):e21628.
359. Hu D, Ikizawa K, Lu L, Sanchirico ME, Shinohara ML, Cantor H. Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat Immunol. 2004;5(5):516-23.
360. Panoutsakopoulou V, Huster KM, McCarty N, Feinberg E, Wang R, Wucherpfennig KW, Cantor H. Suppression of autoimmune disease after vaccination with autoreactive T cells that express Qa-1 peptide complexes. J Clin Invest. 2004;113(8):1218-24.
361. Zang YC, Hong J, Rivera VM, Killian J, Zhang JZ. Human anti-idiotypic T cells induced by TCR peptides corresponding to a common CDR3 sequence motif in myelin basic protein-reactive T cells. Int Immunol. 2003;15(9):1073-80.
362. Kumar V, Sercarz EE. The involvement of T cell receptor peptide-specific regulatory CD4+ T cells in recovery from antigen-induced autoimmune disease. J Exp Med. 1993;178(3):909-16.
363. Kumar V, Stellrecht K, Sercarz E. Inactivation of T cell receptor peptide-specific CD4 regulatory T cells induces chronic experimental autoimmune encephalomyelitis (EAE). J Exp Med. 1996;184(5):1609-17.
364. Kumar V, Sercarz E. Induction or protection from experimental autoimmune encephalomyelitis depends on the cytokine secretion profile of TCR peptide-specific regulatory CD4 T cells. J Immunol. 1998;161(12):6585-91.
365. Buenafe AC, Tsaknaridis L, Spencer L, Hicks KS, McMahan RH, Watson L, et al. Specificity of regulatory CD4+CD25+ T cells for self-T cell receptor determinants. J Neurosci Res. 2004;76(1):129-40.
366. Buenafe AC, Andrew S, Offner H, Vandenbark AA. Regulatory T cells play a role in T-cell receptor CDR2 peptide regulation of experimental autoimmune encephalomyelitis. Immunology. 2012;135(2):168-79.
367. Walker LS, Abbas AK. The enemy within: Keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol. 2002;2(1):11-9.
368. Vandenbark AA. TCR peptide vaccination in multiple sclerosis: Boosting a deficient natural regulatory network that may involve TCR-specific CD4+CD25+ Treg cells. Curr Drug Targets Inflamm Allergy. 2005;4(2):217-29.
369. Mor F, Reizis B, Cohen IR, Steinman L. IL-2 and TNF receptors as targets of regulatory T-T interactions: Isolation and characterization of cytokine receptor-reactive T cell lines in the Lewis rat. J Immunol. 1996;157(11):4855-61.
370. Hong J, Zang YC, Nie H, Zhang JZ. CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis. Proc Natl Acad Sci U S A. 2006;103(13):5024-9.
371. Hong J, Li H, Chen M, Zang YC, Skinner SM, Killian JM, et al. Regulatory and pro-inflammatory phenotypes of myelin basic protein-autoreactive T cells in multiple sclerosis. Int Immunol. 2009;21(12):1329-40.
372. Mimran A, Mor F, Carmi P, Quintana FJ, Rotter V, Cohen IR. DNA vaccination with CD25 protects rats from adjuvant arthritis and induces an antiergotypic response. J Clin Invest. 2004;113(6):924-32.
373. Chen G, Li N, Zang YC, Zhang D, He D, Feng G, et al. Vaccination with selected synovial T cells in rheumatoid arthritis. Arthritis Rheum. 2007;56(2):453-63.
374. Herkel J, Brunner S, Meyer zum Buschenfelde KH, Lohse AW. Humoral mechanisms in T cell vaccination: Induction and functional characterization of anti-lymphocytic autoantibodies. J Autoimmun. 1997;10(2):137-46.
375. Brosh N, Eilat E, Zinger H, Mozes E. Characterization and role in experimental systemic lupus erythematosus of T-cell lines specific to peptides based on complementarity-determining region-1 and complementarity-determining region-3 of a pathogenic anti-DNA monoclonal antibody. Immunology. 2000;99(2):257-65.
376. Jambou F, Cohen-Kaminsky S. Immunoregulation by Vbeta specific antibodies in myasthenia gravis: Mining physiological T cell homeostasis for TCR specific therapy. Cell Mol Biol. 2003;49(2):181-92.
377. Coutinho A. Will the idiotypic network help to solve natural tolerance? Trends Immunol. 2003;24(2):53-4.
378. Cohn M. A commentary on the Zinkernagel-Hengartner “Credo 2004.” Scand J Immunol. 2005;61(6):477-84 [author reply 85-91].
379. Tsujihata Y, So T, Hashimoto Y, Ueda T, Imoto T. A single amino acid substitution in a self protein is sufficient to trigger autoantibody response. Mol Immunol. 2001;38(5):375-81.
380. Herzog S, Jumaa H. Self-recognition and clonal selection: Autoreactivity drives the generation of B cells. Curr Opin Immunol. 2012;24(2):166-72.
381. Di Rosa F, Pabst R. The bone marrow: A nest for migratory memory T cells. Trends Immunol. 2005;26(7):360-6.
382. Collis AV, Brouwer AP, Martin AC. Analysis of the antigen combining site: Correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. J Mol Biol. 2003;325(2):337-54.
383. Ippolito GC, Schelonka RL, Zemlin M, Ivanov, II, Kobayashi R, Zemlin C, et al. Forced usage of positively charged amino acids in immunoglobulin CDR-H3 impairs B cell development and antibody production. J Exp Med. 2006;203(6):1567-78.